Navigation Links
Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results

DANBURY, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today reported fourth quarter and fiscal year ended September 30, 2007 financial results, updated pipeline progress and disclosed 2008 objectives.

"In 2007, our first year as a public company, we advanced our pipeline and achieved critical corporate objectives," stated Dr. Solomon Steiner, CEO and Chairman of Biodel. "The significant milestones reached include our successful initial public offering, the issuance of Patent No. 7,279,457 encompassing VIAject(TM) and VIAtab(TM), the expansion of the pivotal VIAject(TM) trials into Europe and Asia, and the presentation of additional positive clinical data from our VIAject(TM) program. We look forward to completing the Phase III VIAject(TM) clinical trials and expect to file a New Drug Application for VIAject(TM) by calendar year end 2008."

Fourth Quarter and Full Year Financial Results

Biodel reported a net loss for the fourth quarter ended September 30, 2007 of $8.4 million, or $0.42 per share, as compared to a net loss of $3.9 million, or $0.36 per share, for the comparable period in the prior year. The fourth quarter 2007 net loss includes $0.6 million of non-cash stock-based compensation expenses.

Net loss applicable to common stockholders for the year ended September 30, 2007 was $27.0 million, or $1.76 per share, as compared to $8.7 million, or $1.05 per share for the year ended September 30, 2006. The net loss includes non-cash charges of $4.2 million, or $0.21 per share, of stock-based compensation and $4.5 million, or $0.22 per share from a deemed dividend charge related to the exercise of warrants at a discounted exercise price.

Biodel reported no revenue during the three months and years ended September 30, 2007 and September 30, 2006.

Research and development expenses were $7.1 million for the three months ended September 30, 2007, compared to $2.3 million for the same period in the prior year. For the 2007 fiscal year, research and development expenses were $15.9 million, compared to $6.0 million for 2006. Both the increase in quarterly and annual expenses were primarily due to costs related to Biodel's two continuing pivotal Phase III clinical trials for VIAject(TM) and personnel-related expenses. To support the research and development projects and clinical trials, Biodel increased the research and development and clinical staff from eight, in fiscal year 2006, to eighteen. Currently, there are twenty-four research and development and clinical staff.

General and administrative expenses totaled $2.3 million for the three months ended September 30, 2007, compared to $0.6 million for the same period in the prior year. General and administrative expenses totaled $8.4 million for the year ended September 30, 2007, compared to $1.5 million for the comparable period in the prior year. The increase for both the quarter and full year expenses was primarily attributable to $1.0 million and $5.9 million, respectively, in personnel-related expense, including non-cash stock- based compensation expense and performance-based bonus accruals. The non-cash expense for the fiscal year included a $1.7 million charge for options granted to the Board of Directors in May 2007 that vested immediately. The balance of the increase was due to increases in accounting, legal and consulting fees associated with the preparation to become and operate as a public company.

In fiscal year 2007, Biodel increased its general and administrative personnel from eight to twelve. This was associated with the preparation to become and operate as a publicly traded company and further support research and development and clinical projects. Currently, there are seventeen general and administrative personnel.

At the end of fiscal year 2007, Biodel had cash and cash equivalents of $80.0 million and 20.2 million shares outstanding.

Fiscal Year 2007 Corporate & Clinical Highlights

The Company reported progress in advancing the clinical development of its lead product candidates and success in executing its corporate goals:

* Filed an investigational new drug ("IND") application, amended an

existing IND, and initiated pharmacokinetics and pharmacodynamics trials

to develop a suite of six VIAject(TM) products for commercialization:

VIAject(TM) A: Single Vial 10ml (liquid; refrigerated or frozen)

-- 100 IU/ml

-- 25 IU/ml

VIAject(TM) B: Twin Vials 10ml (lyophilized cake and diluent; no

refrigeration required)

-- 100 IU/ml

-- 25 IU/ml

Pen Cartridge Systems 3ml

-- 100 IU/ml (1 IU increments)

-- 25 IU/ml (1/4 IU increments)

* Presented positive clinical data from the VIAject(TM) program:

* At the annual meeting of the American Diabetes Association, the

Company presented additional interim results from its Phase III

clinical trials for VIAject(TM) that demonstrated statistically

significant daily meal-time dose reductions in patients with Type

1 and Type 2 diabetes using VIAject(TM), significantly fewer mild

and moderate hypoglycemic events and reduction in weight gain.

* At the annual meeting of the European Association for the Study of

Diabetes, the Company presented VIAject(TM) Phase II meal study

data that demonstrated statistically significant and clinically

relevant improved glycemic control compared to regular human

insulin (Humulin(R) R) and lispro (Humalog(R)).

* At the annual Diabetes Technology Meeting, after the close of

fiscal year 2007, the Company presented the results of a meal

study comparing VIAject(TM) head-to-head with Humalog(R) in

patients who regularly use Humalog(R) as their prandial insulin.

VIAject(TM) produced significantly superior glycemic control,

reduced the risk of hypoglycemia, and reduced glycemic excursions

compared to Humalog(R).

* Expanded the Company's two ongoing pivotal Phase III clinical trials

of VIAject(TM) into Europe and Asia.

* The United States Patent and Trademark Office issued Patent No.

7,279,457 encompassing VIAject(TM) and VIAtab(TM).

* Completed the Company's initial public offering of 5,750,000 shares of

its common stock at a price to the public of $15.00 per share. Net

proceeds from the offering, after underwriting discounts, commissions

and expenses, totaled approximately $78.8 million (net).

Calendar Year 2008 Corporate Goals

The company provided details regarding critical 2008 calendar year objectives:

* Complete enrollment of the two pivotal Phase III clinical trials of

VIAject(TM) for Type 1 and Type 2 diabetic patients.

* Complete the pharmacokinetics and pharmacodynamics trials of the suite

of six VIAject(TM) products.

* Announce data from the two completed pivotal Phase III clinical trials

of VIAject(TM). (The Company will not present any additional interim

data prior to the completion of both Phase III trials.)

* File a New Drug Application for VIAject(TM).

* Finalize commercialization strategy for VIAject(TM).

Conference Call and Webcast Information

Biodel's senior management will host a conference call on December 11, 2007 beginning at 4:30 p.m., Eastern Standard Time, to discuss these financial results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 1-877-718-5104 (United States) or 1-719-325-4779 (international). To access the call by live audio webcast, please log on to the Investor section of the Company's website at An archived version of the audio webcast will be available at Biodel's website through January 11, 2007.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in a Phase I clinical trial and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure additional patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.


Biodel Inc.

(A Development Stage Company)

Balance Sheets

(in thousands, except share and per share amounts)

September 30,

2006 2007



Cash and cash equivalents $17,539 $80,022

Prepaid and other assets 79 505

Total current assets 17,618 80,527

Property and equipment, net 644 1,717

Intellectual property, net 208 262

Deferred public offering costs 189 -

Total assets $18,659 $82,506



Accounts payable $1,357 $2,187

Accrued expenses:

Clinical trial expenses - 1,164

Payroll and related 186 822

Accounting and legal fees - 335

Other 255 680

Income taxes payable 13 95

Due to related party 250 -

Deferred compensation 250 -

Total current liabilities 2,311 5,283


Stockholders' equity:

Preferred stock, $.01 par value; 50,000,000 shares


Series A convertible preferred stock, 1,050,000 shares

authorized, 569,000 and 0 shares issued

and outstanding, respectively, with a liquidation

preference of $2,845 and an 8% non-cumulative

dividend 6 -

Series B convertible preferred stock, 6,500,000 shares

authorized, 6,198,179 and 0 shares issued and

outstanding, respectively, with a

liquidation preference of $24,421 62 -

Common stock, $.01 par value; 100,000,000 shares

authorized; 5,360,430 and 20,160,836 issued

outstanding, respectively 54 202

Additional paid-in capital 29,054 116,854

Deficit accumulated during the development stage (12,828) (39,833)

Total stockholders' equity 16,348 77,223

Total liabilities and stockholders' equity $18,659 $82,506

Biodel Inc.

(A Development Stage Company)

Statements of Operations

(in thousands, except share and per share amounts)

December 3,






2005 2006 2007 2007

Revenue $ - $ - $ - $ -

Operating expenses:

Research and development 2,666 5,987 15,939 25,172

General and administrative 724 1,548 8,386 10,851

Total operating expenses 3,390 7,535 24,325 36,023

Other (income) and expense:

Interest and other income (9) (182) (1,902) (2,093)

Interest expense - 78 - 78

Loss on settlement of debt - 627 - 627

Operating loss before tax provision (3,381) (8,058) (22,423) (34,635)

Tax provision 2 10 125 138

Net loss (3,383) (8,068) (22,548) (34,773)

Charge for accretion of beneficial

conversion rights - (603) - (603)

Deemed dividend - warrants - - (4,457) (4,457)

Net loss applicable to common

stockholders $(3,383) $(8,671) $(27,005) $(39,833)

Net loss per share - basic and

diluted $(0.56) $(1.05) $(1.76)

Weighted average shares outstanding

- basic and diluted 6,080,746 8,252,113 15,354,898


Investors, should contact Clay A. Kramer,, or Media, Carney Noensie,, both of Burns McClellan, Inc., +1-212-213-0006, for Biodel Inc.

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Biodel Inc. Announces Appointment of Gerard Michel as CFO, VP of Corporate Development and Treasurer
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. Haemacure Reports Third Quarter 2007 Results
4. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
5. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
6. MDS Reports Third Quarter 2007 Results
7. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
8. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
9. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
11. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
Post Your Comments:
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology: